Arcadia Biosciences opened lower at $0.19, compared with its previous close of $0.24. In the last trading session, the stock traded between $0.18 and $0.23. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Arcadia Biosciences is now worth
$ 0.29
Resulting in a loss of
$ 99.71 (99.71%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.02 (-6.64%)
Day High
$0.23
Day Low
$0.18
Day Open
$0.19
Prev Close
$0.24
Volume
25,33,061
1W Return
42.31%
1M Return
0.00%
3M Return
-66.92%
6M Return
-79.06%
1Y Return
-93.93%
Fundamentals
Market Cap ($ Mn)
1
PE Ratio
-
PB Ratio
1.81
PEG Ratio
-
ROE
-39.99%
ROCE
-33.17%
EPS (TTM)
$-2.87
Investment Returns
1 Week
42.31%
1 Month
0.00%
3 Months
-66.92%
6 Months
-79.06%
9 Months
-87.09%
Financials
Quarterly
All values in $ Mn
1.2
Mar 25
1.5
Jun 25
1.3
Sep 25
0.9
Dec 25
1.1
Mar 26
1.4
Jun 26
Updates
14Aug
Arcadia Biosciences Q2 EPS improves to $(2.09) as sales dip 1%
Arcadia Biosciences reported Q2 2026 EPS of $(2.09), up from $(3.26) YoY, while sales fell 0.82% to $1.443 million. The net loss widened to $6.3 million due to non-operating items, but operational cash usage was low at $319,000. The company holds $4.2 million in cash following a $4 million private placement.
3mo ago
27Jun
Arcadia Biosciences files prospectus for 11.92M share resale
Arcadia Biosciences filed a prospectus allowing selling stockholders to offer up to 11.92M shares of common stock for resale. The company will not receive proceeds from the sale.
4mo ago
13Jun
Arcadia Biosciences closes $4 million private placement
Arcadia Biosciences, Inc. closed a $4 million private placement priced at-the-market under Nasdaq rules, issuing 3,883,496 shares of common stock or pre-funded warrants and associated Series A-1 and Series A-2 preferred investment options. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
